Tobias Bjorklund - Novozymes A/S Head of Investor Relations

All Insiders . USA . 
Stock . Novozymes AS B . Stakeholders . Insider . Tobias Bjorklund
NVZMF Stock  USD 60.65  0.45  0.74%   

Executive

Tobias Bjorklund is Head of Investor Relations of Novozymes AS B since 2017.
Tenure 8 years
Phone45 44 46 00 00
Webhttps://www.novozymes.com

Novozymes A/S Management Efficiency

The company has return on total asset (ROA) of 0.1062 % which means that it generated a profit of $0.1062 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2789 %, meaning that it generated $0.2789 on every $100 dollars invested by stockholders. Novozymes A/S's management efficiency ratios could be used to measure how well Novozymes A/S manages its routine affairs as well as how well it operates its assets and liabilities.
Novozymes AS B has accumulated 7.31 B in total debt with debt to equity ratio (D/E) of 0.59, which is about average as compared to similar companies. Novozymes AS B has a current ratio of 1.18, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Novozymes A/S until it has trouble settling it off, either with new capital or with free cash flow. So, Novozymes A/S's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Novozymes AS B sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Novozymes to invest in growth at high rates of return. When we think about Novozymes A/S's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Tobias ErfurthSymrise Ag PK
N/A
John VeldenLinde plc Ordinary
N/A
Joanne MullenEcolab Inc
N/A
Victoria OssadnikLinde plc Ordinary
52
Karin GriggelLinde plc Ordinary
N/A
Karl SchmittSherwin Williams Co
N/A
John KramerRPM International
N/A
Paul LangSherwin Williams Co
48
Christina KongEcolab Inc
N/A
Desiree BacherLinde plc Ordinary
54
Franz FehrenbachLinde plc Ordinary
71
Katie McDonaldAir Products and
N/A
Kimberly FoleyLyondellBasell Industries NV
58
AnnKristin AchleitnerLinde plc Ordinary
54
Gregory CookEcolab Inc
56
Evgeny AnAir Products and
N/A
Kathie RogersRPM International
N/A
Philippe JostSika AG
52
Robert MassyPPG Industries
N/A
Ramaprasad VadlamannatiPPG Industries
62
Philippe JostSika AG ADR
52
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States. Novozymes AS B [NVZMF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Return On Equity0.28
Return On Asset0.11

Novozymes AS B Leadership Team

Elected by the shareholders, the Novozymes A/S's board of directors comprises two types of representatives: Novozymes A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novozymes. The board's role is to monitor Novozymes A/S's management team and ensure that shareholders' interests are well served. Novozymes A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novozymes A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pedro Fernandes, Head America
Tobias Bjorklund, Head of Investor Relations
Ester Baiget, Pres CEO
Tue Micheelsen, VP Marketing
Sebastian Sderberg, VP Acquisitions
Tina Fanoe, Executive Vice President Agriculture & Bioenergy
Graziela Malucelli, Supply Operations
Anders Lund, Executive Vice President Household Care & Technical Industries
Morten Rasmussen, Sustainability People
MSc MSc, Ex CFO

Novozymes Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Novozymes A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.28
Return On Asset0.11
Profit Margin0.21 %
Operating Margin0.26 %
Current Valuation14.47 B
Shares Outstanding222.86 M
Shares Owned By Insiders8.04 %
Shares Owned By Institutions42.30 %
Price To Earning33.38 X
Price To Book6.19 X

Currently Active Assets on Macroaxis

CRMSalesforce
CCitigroup
GMGeneral Motors
WDWalker Dunlop
MSFTMicrosoft

Other Information on Investing in Novozymes Pink Sheet

Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY